 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Invivyd, Inc. (NASDAQ:IVVD  Get Free Report) was the recipient of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling...

Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 6.6% in October

Recap: Invivyd Q3 Earnings

Enrollment completed in CANOPY Phase 3 pivotal clinical trial investigating VYD222 for the prevention of symptomatic COVID-19Company expects to have initial CANOPY primary endpoint data by late 2023...

Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights

WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...

Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...

Invivyd to Participate in Upcoming Investor Conferences

Maverick Capital Ltd. bought a new position in shares of Invivyd, Inc. (NASDAQ:IVVD  Free Report) in the first quarter, according to the company in its most recent disclosure with the...

Maverick Capital Ltd. Invests $2.27 Million in Invivyd, Inc. (NASDAQ:IVVD)

WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...

Invivyd Appoints William Duke as Chief Financial Officer

Invivyd, Inc. (NASDAQ:IVVD Free Report) Analysts at HC Wainwright decreased their Q3 2023 earnings per share (EPS) estimates for Invivyd in a research report issued on Monday, August 14th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.55) per share for ...

HC Wainwright Weighs in on Invivyd, Inc.'s Q3 2023 Earnings (NASDAQ:IVVD)

Invivyd, Inc. (NASDAQ:IVVD  Free Report)  Equities researchers at HC Wainwright boosted their Q4 2024 earnings estimates for shares of Invivyd in a research report issued on Monday...

Q4 2024 EPS Estimates for Invivyd, Inc. Boosted by Analyst (NASDAQ:IVVD)

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Watchers	4,718
52-Wk Low	$0.9802
52-Wk High	$2.68

Market Cap	$167.37M
Volume (M)	112,976.00
52-Wk High	$2.68
52-Wk Low	$0.9802

IVVD Invivyd Inc

About

Feed

News

Sentiment

Earnings

Fundamentals